Featuring interviews with Alan Venook, MD, Tom Weber, ANP-BC and additional comments by two patients with colon cancer. (Audio Content)
OVERVIEW OF ACTIVITY
Colorectal cancer is one of the most rapidly evolving fields in oncology nursing. Published results from ongoing clinical trials lead to the continuous emergence of new therapeutic agents and changes in the indications for existing treatments. In order to offer optimal patient care, oncology nurses must be well informed of these advances, including the relative efficacy of new agents and regimens and strategies to minimize and manage associated toxicities. This program provides nurses with access to the latest research developments and opinions of oncology healthcare professionals with experience and expertise in the field, in addition to perspectives of patients undergoing treatment.
PURPOSE STATEMENT
To present the most current research developments in colorectal cancer and to provide the perspectives of medical oncologists, oncology nurses and patients on the diagnosis and treatment of colorectal cancer.
EDUCATIONAL OBJECTIVES FOR THIS ISSUE OF COLORECTAL CANCER UPDATE FOR NURSES
ACCREDITATION STATEMENTS
Research To Practice is an approved provider of continuing nursing education by NJSNA, an accredited approver, by the American Nurses Credentialing Center’s Commission on Accreditation.
This activity for 1.7 contact hours is provided by Research To Practice. Provider Number: P215-01/07-10.
HOW TO USE THIS CNE ACTIVITY
CME credit is no longer available for this issue
This is an audio CNE program. This website contains CNE information, including learning objectives, faculty disclosures, a Post-test and an Educational Assessment and Credit Form, as well as links to relevant abstracts and full-text articles.
CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CNE activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY — Mr Weber had no real or apparent conflicts of interest to disclose. The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr Venook — Advisory Committee: Amgen Inc, ImClone Systems Incorporated; Grant Funding: Genentech BioOncology; Paid Research: Bayer Pharmaceuticals Corporation, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc, Pfizer Inc.
EDITOR — Neil Love: Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME/CNE activities from the following commercial interests: Abraxis BioScience, AstraZeneca Pharmaceuticals LP, Aureon Laboratories Inc, Bayer Pharmaceuticals Corporation/Onyx Pharmaceuticals Inc, Biogen Idec, Bristol-Myers Squibb Company, Celgene Corporation, Eisai Inc, Eli Lilly and Company, Genentech BioOncology, Genomic Health Inc, GlaxoSmithKline, ImClone Systems Incorporated, Merck and Company Inc, Millennium Pharmaceuticals Inc, Novartis Pharmaceuticals Corporation, Ortho Biotech Products LP, OSI Oncology, Pfizer Inc, Roche Laboratories Inc, Sanofi-Aventis, Synta Pharmaceuticals Corp and Wyeth.
RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.
This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
This program is supported by educational grants from Genentech BioOncology and Sanofi-Aventis.
Hardware/Software Requirements:
An Internet connection that is at least 28.8 Kbps
A monitor set to 1280 x 1024 pixels or more
Netscape 7.x or newer, Internet Explorer 5.x or newer, or Firefox
Macromedia Flash plug-in 6.0 or greater
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio
Last review date: February 2009
Expiration date: February 2010
Featuring interviews with Alan Venook, MD, Tom Weber, ANP-BC and additional comments by two patients with colon cancer. (Audio Content)